Early Detection: A strategy to reduce risk and severity? by Piller, Neil et al.
Despite changes in surgical techniques, 
radiotherapy targeting and the apparent 
earlier detection of cancers, secondary 
lymphoedema is still a significant problem 
for about 20–30% of those who receive 
treatment for cancer, although the incidence 
and prevalence does seem to be falling. The 
figures above generally relate to detection 
of an enlarged limb or other area, but it 
seems that about 60% of all patients also 
suffer other problems with how the limb 
feels, what can or cannot be done with it 
and a range of social or psychological issues. 
Often these ‘subjective’ changes occur before 
the objective ones, such as a change in arm 
volume or circumference.
 
For most of those treated for cancer 
lymphoedema does not develop immediately, 
and, while about 60–70% develop it in 
the first few years, some do not develop 
lymphoedema for up to 15 or 20 years. 
Those who will develop clinically manifest 
lymphoedema in the future are, for 
some time, in a latent or hidden phase of 
lymphoedema. 
 
There also seems to be some risk factors 
which are indicators for a higher likelihood 
of lymphoedema post treatment, including 
oedema at the surgical site, arm dominance, 
age, skin conditions, and body mass index 
(BMI). 
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What are likely to be the 
best measurement options 
to detect pre-clinical 
lymphoedema, or the risk of 
it developing at some later 
stage? 
VK:   At present the two best 
measurement options seem to be limb 
volume and bioimpedance.
Limb volume can be calculated from 
circumferential tape measurements but 
its reliability has been questioned, with 
particular respect to inter-observer 
variation. While this may not be too 
important when this technique is used 
clinically to monitor the response to 
treatment of a significantly swollen 
limb, it may not be sensitive enough to 
detect small changes which may indicate 
early lymphoedema in a minimally 
swollen limb. In addition, when using the 
‘unaffected’ limb as a control, there are 
difficulties in defining what constitutes 
‘established’ lymphoedema, e.g. >10% 
excess volume (Hayes, 2008), and 
this is further complicated when the 
impact of limb dominance is considered 
(as described in the introduction). 
Nevertheless, taking measurements pre-
operatively and comparing these with 
subsequent recordings may facilitate the 
early detection of changes.
Indeed, in the ALMANAC trial 
using this method (Mansel, 2006), the 
identification of early arm swelling 
(4–5%) predicted that 53% of such 
cases would subsequently develop 
lymphoedema (defined by an arm 
swelling of ≥2cm circumference) by 18 
months, whereas 6% arm swelling at 
three or six months predicted 60% of 
lymphoedema cases at 18 months of 
follow-up.
The use of an optoelectronic volume 
measuring device (e.g. the perometer) 
may improve the accuracy and reliability 
of limb volume measurements and, 
therefore, may be more predictive, but 
these devices are not readily available in 
most hospitals in the UK and may not 
represent a practical proposition.
There is evidence that changes 
in bioelectrical impedance may be 
more sensitive in the early diagnosis 
of lymphoedema following surgery for 
breast cancer (Cornish et al, 2000). 
Again, comparing pre- and post-
operative measures seems to be the 
best approach to this. Furthermore, one 
company has developed a bioimpedance 
index (L-DexTM, Impedimed Inc). The 
normal range of this index is based on a 
study of a population of healthy women 
and an abnormal result is defined as 
3 standard deviations from the means 
(L-Dex >10). At present, devices to 
measure bioimpedance are not routinely 
available but could represent a useful 
way forward.
TR:   I interpret best as being what is 
most available at village level, where the 
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Sometimes a person presents who appears 
to have a swelling on the operated side, 
but when the right questions are asked it is 
discovered that that is their dominant (or 
stronger) arm in the first place (and thus 
naturally has more muscle and a greater 
circumference and volume even without 
anything having been done). Sometimes 
patients are sent along an unnecessary 
treatment pathway with unnecessary 
anxiety due to an incorrect diagnosis of 
lymphoedema.
 
Irrespective of this, some person’s arms 
are different in size, volume and ability 
long before any cancer has been detected. 
‘Arm dominance’ is often misunderstood 
and listed as the hand with which a person 
writes. However, it is their strength or 
muscular dominance that is of interest. A 
similar situation can apply for the legs in 
terms of dominance.
NP
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VK: At present the two best measurement options seem to be limb volume and bioimpedance.
TR: I interpret best as being what is most available at village level, where the effective tools used in well-equipped centres are unaffordable.
SH:  ... bioimpedance spectroscopy is developing a track record that demonstrates it meets the necessary research and clinical criteria... 
SR: The greatest hope for predicting lymphoedema may reside in as yet undiscovered biomarkers or genetic polymorphisms...
effective tools used in well-equipped 
centres are unaffordable. There is no 
better tool than carefully questioned, 
listened to and recorded history-taking. 
If the listener is told that the cancer, the 
surgeon or the radiotherapist focused 
on lymph nodes, it is reasonable to 
suspect secondary lymphoedema will 
be a consequence. If one is told that 
there is immobility, lack of elevation or 
movement, symptoms of heart failure, 
a history of deep vein thrombosis or 
limb trauma, or if there is a story of 
recurrent cellulitis, then it is likely that 
there is lymphoedema secondary to 
overload.
SH:   When deciding which 
method(s) are optimal, several factors 
must be considered, such as the 
accuracy, sensitivity, and specificity of 
the measure, whether the measure 
has been shown to detect ‘subclinical’ 
lymphoedema (before patients report 
symptoms), and whether the measure 
is affordable, transportable, practical 
for clinic use, non-invasive and time-
efficient. While measurement of arm 
volume (particularly by measuring 
limb circumferences) predominates 
as the measure of choice in the 
research literature and clinical practice 
(Langbecker et al, 2008), bioimpedance 
spectroscopy is developing a track 
record that demonstrates it meets 
the necessary research and clinical 
criteria, particularly for diagnosing arm 
lymphoedema following breast cancer 
Hayes et al, 2008a, b).
SR:   It is possible to argue that 
detecting ‘pre-clinical lymphoedema’ and 
determining who is at risk of developing 
lymphoedema at a later stage are 
two different questions, with different 
answers that require the use of different 
scientific and clinical approaches. Let us 
start by addressing the first part of this 
question, about the best measurement 
options to detect ‘pre-clinical 
lymphoedema’, which for purpose of 
this answer I will define as swelling 
yet unnoticed by either patient or 
practitioner. I would suggest that there 
is no ‘gold standard’ best method. The 
choice of method is dependent upon 
many factors, such as the anatomical 
segment of the body that you need to 
measure (e.g. limb vs head or neck) and 
resources available to clinicians. 
Anatomical location: There may be 
several ‘acceptable’ methods for limb 
lymphoedema, most of which involve 
some variation of volume or impedance 
measurement (Ridner et al, 2007). 
Unfortunately, for areas such as the 
head and neck, there may not be any 
proven effective measurement method, 
and photography may be a reasonable 
‘measurement’ option, if you are able 
to store or retain patient photographs 
in the medical record to allow for 
comparisons over time (Lymphoedema 
Framework, 2006). 
Resources available to clinicians: 
infrared scanning devices and 
bioelectrical impedance devices, while 
excellent measurement methods, are 
costly. Many treatment centres may 
not have access to them, particularly 
in rural and similarly underserved 
areas. So, the question is, can we set as 
a universal standard the use of these 
devices? Probably not. In some cases, 
tape circumferential measurements 
may be best, if use of this low-tech 
approach ensures measurements can 
and will be done routinely. Developing 
and using a standardised procedure for 
measurement in a practice setting is key, 
regardless of which method the setting 
chooses to use.
The second part of this question 
concerns how to best predict the risk 
of developing lymphoedema at some 
point of time after trauma to the 
lymphatics has occurred. The greatest 
hope for predicting lymphoedema 
may reside in as yet undiscovered 
biomarkers or genetic polymorphisms, 
that are common to those who 
develop secondary lymphoedema 
and uncommon in those who do not. 
At this time, we are unable to reliably 
predict this.
When is the best time 
to undertake these 
measurements? 
VK:   As stated above, a baseline 
measurement pre-operatively is ideal 
with subsequent measurements taken at 
the time of follow-up appointments, e.g. 
at three months, six months, one year, 18 
months, etc. It is recognised that most 
patients who develop lymphoedema 
will develop it in the first few years. In 
the UK, routine breast cancer follow-
up is often limited to three years by 
specialist breast cancer clinics (National 
Institute of Clinical Excellence [NICE], 
2002), so the detection of later onset 
lymphoedema is likely to have to rely 
upon subjective reports by patients.
TR:   Wound healing responses such 
as inflammation and scarring take a 
year to settle. Measurements of swelling 
should not be interpreted as certainly 
lymphatic failure until after that time.
SH:   We know from work involving 
women with breast cancer that the 
majority of lymphoedema cases (70–
80%) occur within the first 12 months 
post-cancer diagnosis, with up to two-
thirds of cases occurring by six months 
post-diagnosis (Clark et al, 2005; Hayes 
et al, 2008b). Therefore, integrating 
a lymphoedema assessment during 
routine follow-up visits would seem 
beneficial for tracking lymphoedema 
status. However, there are two 
important caveats: (1) if lymphoedema 
is assessed too early following surgery 
or radiation treatment, there is the risk 
of misclassifying normal post-treatment 
swelling as lymphoedema; and (2) taking 
baseline measurements prior to the start 
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VK: Some symptoms may be related to the cancer treatment rather than lymphoedema per se, e.g. heaviness, tightness, aching, stiffness and limited mobility. 
TR: Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and scarification by traditional healers are significant risk factors...
SH: Evidence does consistently support increased risk of secondary lymphoedema with  more extensive surgery, radiation therapy and other arm symptoms...
SR: ... unless there is a plan for post-treatment measurement, pre-treatment measurement provides no added value to patient treatment and is unlikely, in and of   
 itself, to improve patient outcomes. 
of any cancer treatment, irrespective 
of the measure used, significantly aids 
the ability to detect the development 
of lymphoedema post-treatment. So, 
it would seem that a pre-treatment 
measurement session, followed by 
assessments at regular intervals starting 
somewhere between two and six 
months depending on treatment, may 
be optimal, with the duration of the 
interval perhaps increasing after 12 
months post-diagnosis. 
SR:   Some cancer patients at long-
term risk for lymphoedema do not 
experience surgery as their first method 
of treatment, some have chemotherapy 
before their surgical procedures. 
Due to this, any measurement 
would ideally be performed prior to 
initiation of any cancer treatment, 
including chemotherapy. Given the 
normal variation in limb size and face 
and neck asymmetry, pre-treatment 
measurements, or in some cases 
photography, are needed for all types 
of at-risk cancer patients. Pre-treatment 
measurement allows for post-treatment 
measurements to be compared 
to the patient’s own normative 
values. However, it is important 
when conducting post-treatment 
measurements to have a good 
understanding of the normal ‘healing 
trajectory’ of patients. This is necessary 
to avoid a ‘false positive’ diagnosis of 
lymphoedema. Such ‘false positives’ can 
occur when acute swelling/inflammation 
is mistakenly labelled lymphoedema. 
This causes the patient unnecessary 
psychological distress.
Integration of lymphoedema 
assessment as routine standard care 
is highly desirable. In terms of post-
treatment measurements, measurements 
are most likely to be done if they 
take place at all scheduled follow-
up appointments. Post-treatment 
measurement should always use the 
same method that was used pre-
treatment, although clinicians may 
want or need to employ additional 
methods under certain circumstances. 
The timeframe for post-treatment 
measurements may be driven by follow-
up intervals that vary by the type of 
cancer and the internal procedures 
in the healthcare system or setting 
providing the care. The key point is 
that unless there is a plan for post-
treatment measurement, pre-treatment 
measurement provides no added value 
to patient treatment and is unlikely, 
in and of itself, to improve patient 
outcomes.
What are the best predictors 
of outcome, i.e. the risk of 
developing lymphoedema — 
objective measures of physical 
parameters or subjective 
parameters?
VK:   Although there is some 
evidence that subjective changes in the 
limb may be associated with fibrosis 
and other changes in the subcutaneous 
tissues without affecting limb volume 
(Tassenoy, 2008), there is other evidence 
that symptoms alone are not necessarily 
an accurate indicator of swelling (Kissin 
et al, 1986). Some symptoms may 
be related to the cancer treatment 
rather than lymphoedema per se, e.g. 
heaviness, tightness, aching, stiffness 
and limited range of movement. These 
may be as common in patients without 
lymphoedema as those with (Armer and 
Fu, 2005).
Physical measures of limb volume 
and bioimpedance, as described above, 
may therefore be more helpful.
TR:   The risk of developing 
lymphoedema is detailed in the list 
of things to avoid which is usually 
given to the patient. I rate venous 
overload and recurrent barrier breach 
by infective organisms or irritants as 
factors that increase risk. Becoming 
obese is definitely to be avoided. Human 
immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/
AIDS) and scarification by traditional 
healers are significant risk factors in 
some of the clinics that I have attended 
in Africa.
SH:   The aetiology of secondary 
lymphoedema seems to be multifactorial, 
with contributory factors including 
pre-existing conditions as well as 
acquired abnormalities (Rockson, 1998). 
Unfortunately, to date, the nature 
of the relationships between many 
patient, treatment and behavioural 
characteristics, such as age, body mass 
index (BMI), treatment on the dominant 
side, socioeconomic status, social 
support, and participation in physical 
activity, are inconsistent in the scientific 
literature (Hayes et al, 2008a; Hayes, 
2008). Evidence does consistently 
support increased risk of secondary 
lymphoedema with more extensive 
surgery, radiation therapy, and the 
presence of other arm symptoms, such 
as pain, numbness, stiffness, etc (Hayes et 
al, 2008b; Hayes, 2008). 
However, even these consistently 
reported characteristics do not alone 
distinguish who will and who will not 
get lymphoedema, or who will have 
problems with upper-body function. For 
example, in the breast cancer setting, 
those who have sentinel lymph node 
biopsy are at lower risk of developing 
lymphoedema, but some of them still 
may get it, and the prevalence of arm 
symptoms is high even among women 
who never develop lymphoedema 
(ranging between 35% for tingling 
and 62% for numbness). Therefore, 
lymphoedema is most likely to be 
diagnosed early when pre-treatment 
and regular post-treatment assessment 
occurs, considering the individual 
patient’s treatment and behavioural 
characteristics, as well as report of 
additional symptoms.
Journal of Lymphoedema, 2009, Vol 4, No 1 91
Debate C.indd   5 9/4/09   09:03:08
92 Journal of Lymphoedema, 2009, Vol 4, No 1
Journal of Lymphoedema DEBATE
SR:   Right now, we simply do not 
know how to ‘predict’ which patients are 
the most likely to develop lymphoedema 
after cancer treatment, or for that 
matter, after any other traumatic injury 
that damages the lymphatic system. We 
think that, for certain cancer patients, 
the more extensive the treatment 
(e.g. more lymph nodes removed, 
mastectomy vs lumpectomy), the 
more risk patients have for developing 
lymphoedema (Ridner, 2002). It is also 
possible that comorbid conditions such 
as age, obesity, cardiac problems, and 
inflammatory disease may be associated 
with lymphoedema (Ridner and Dietrich, 
2008), but longitudinal studies are 
needed to shed further light on these 
relationships.
Changes over time in objective 
physical measurements, such as volume 
or impedance values, may help us 
detect lymphoedema earlier. Regarding 
subjective parameters, such as patient 
reported symptoms, I would argue that 
some symptoms, such as self-reported 
new onset swelling, or new or different 
sensations in the arm may be warning 
signs of developing lymphoedema. Even 
though breast cancer patients may 
have odd feelings in their arms with 
no identifiable swelling, a change in 
symptoms, in any at-risk individual should 
never be ignored and should trigger 
further assessment.
Unfortunately, however, neither 
objective measures of physical 
parameters nor subjective parameters 
truly ‘predict’ lymphoedema onset 
or risk. They can tell us if changes 
have happened that may cause major 
problems for our patients. The value 
of that knowledge should not be 
underestimated.
What is the evidence from 
long-term follow-up of 
patients who have signs of 
sub-clinical lymphoedema 
that its early detection and 
subsequent intervention 
(to reduce the risk through 
education awareness, etc) 
make any difference to the 
likelihood of clinically manifest 
lymphoedema developing? 
VK:   Much of the current risk 
reduction guidance is aimed at avoiding 
further damage to the lymphatic 
system in the ‘at risk’ limb, e.g. by 
avoiding trauma and minimising the 
risk of infection as much as possible. 
Unfortunately, there is little evidence 
to support the validity of this advice 
and whether it helps to prevent 
lymphoedema developing (Hayes, 2008). 
Other, more interventionist 
approaches may, however, also be worth 
considering. One recent prospective 
observational study using pre- and post-
operative perometer measurements 
looked at the effect of wearing 
graduated compression garments on the 
development of swelling (Stout Gergich 
et al, 2008). Lymphoedema was defined 
as a ≥3% increase in limb volume 
compared with the pre-operative 
measurements (using the contralateral 
limb as a control). This is a much lower 
‘cut-off ’ than is usually used to define 
lymphoedema and may be considered 
‘sub-clinical’ swelling. Those women 
meeting this criterion wore compression 
garments (20–30mmHg compression) 
for a mean duration of 4.4 (±2.9) 
weeks followed by continued use of the 
garment during exercise or if swelling 
appeared. Using this approach, a mean 
arm volume reduction of 4.1% (±8.8%) 
was achieved (<0.0001), and this was 
maintained at an average follow-up of 
4.8 (±4.1) months after the intervention. 
Although this was not a randomised trial, 
there is a suggestion that a short trial of 
a compression garment may treat sub-
clinical lymphoedema. Further work on 
this would help to identify whether such 
an approach is truly preventative.
TR:   In my opinion, more studies are 
needed to produce such evidence.
I agree with VK and SH but would 
add that the patient has to struggle to 
keep up a programme of management. 
One factor that clearly helps in the 
clinic in India described by Narahari 
et al (2007) is a supportive family. The 
supplement accompanying this issue 
emphasises the concept of patient 
participation. 
SH:   At this time the evidence base 
for prevention recommendations is 
limited. There is a clear need for well-
designed, population-based, prospective 
studies to investigate the causal 
relationship between suggested risk 
factors and subsequent development of 
secondary lymphoedema. However, until 
results from such studies are available, 
it seems reasonable for healthcare 
professionals to discuss the rationale and 
relevance of commonly recommended 
preventive strategies, but importantly to 
encourage healthy lifestyle behaviours 
(Hayes, 2008).
With respect to effectiveness 
of treatment, evidence supporting 
the effectiveness of available 
treatment strategies is graded as 
poor to satisfactory (Hayes 2008). 
Nonetheless, treatment guidelines 
exist, and there is some consistency 
in outcomes from research. The bulk 
of evidence demonstrates volume 
reductions following secondary 
lymphoedema treatment, particularly 
when conservative treatment options 
are used (Hayes, 2008), with the most 
recent attention being given to the 
effectiveness of compression in the 
treatment of subclinical lymphoedema 
(Stout Gergich et al, 2008). It is also 
thought that lack of treatment is 
related to secondary lymphoedema 
progression, although this too requires 
further confirmation. However, 
potential adverse consequences, such as 
VK: ... there is a suggestion that a short trial of a compression garment may treat sub-clinical lymphoedema.  
TR: One factor that clearly helps in the clinic in India described by Narahari et al (2007) is a supportive family.
SH: The acceptability of treatment strategies to patients may be as important as monitoring compliance or treatment efficacy to successful outcomes...
SR: The evidence base for true prevention of lymphoedema is virtually non-existent and research is greatly needed in this area.
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VK: There is evidence that lymphoedema causes a significant impact on patients’ quality of life with a vulnerability to recurrent cellulitis, work implications and   
 psychological morbidity (Moffatt et al, 2003).
TR: The people who benefit most are those who can make the lifestyle adjustments to their condition that are necessary to keep a job...
SH: ... early detection of lymphoedema would clearly lead to significant physical, social, emotional, financial, psychological and functional benefits for the individual.
SR: ... patients may benefit from early detection. If they respond to treatment, infections are reduced, and disease progression is slowed.
financial, time and lifestyle burdens, have 
also been associated with treatment for 
secondary lymphoedema (Hayes, 2008) 
and need to be considered. Therefore, 
the acceptability of treatment strategies 
to patients may be as important as 
monitoring compliance or treatment 
efficacy to successful outcomes (as 
defined by reductions in swelling or 
associated symptoms). 
SR:   The evidence base for true 
prevention of lymphoedema is vir tually 
non-existent and research is greatly 
needed in this area. To be of the 
greatest value, such research ideally 
would be experimental in design, with 
longitudinal follow-up over many years, 
as lymphoedema can occur decades 
after treatment. One study, the first 
attempt to scientifically evaluate 
this issue, suggests that wearing a 
compression garment may be helpful 
in reducing the risk of progression, 
but this was not a randomised trial 
and follow-up was not long-term 
(Stout-Gergich, 2008). Because we 
do not have data, we do not know 
if ‘latent’ lymphoedema progresses 
(clinically manifests) in all, or only 
a small percentage of individuals. If 
‘latent’ lymphoedema progresses in all 
individuals, intervention at this early 
stage may be highly desirable. If it 
progresses in only a small percentage 
of individuals, we face an ethical 
dilemma. Do we treat everyone with 
‘latent’ lymphoedema as if they have 
lymphoedema? You might argue, yes, 
this is the only logical response, and 
cite as precedent the treating of ductal 
carcinoma in situ (DCIS) in women. 
You may say, no, as labelling someone 
with lymphoedema, who may never 
become symptomatic, creates undue 
psychological distress and treating 
them with compression garments, etc. 
uses healthcare dollars unwisely. You 
may use ‘watchful waiting’, as done with 
prostate cancer in men, to support this 
position.
What are the likely health 
economic aspects of early 
detection and lymphoedema 
prevention. Who benefits and 
by how much? 
VK:   There is evidence that 
lymphoedema causes a significant 
impact on patients’ quality of life with a 
vulnerability to recurrent cellulitis, work 
implications and psychological morbidity 
(Moffatt et al, 2003). There is also evidence 
that treating lymphoedema reduces the 
incidence of cellulitis (Ko et al, 1998). 
Therefore, it is likely that the early 
detection and prevention of lymphoedema 
is going to reduce this morbidity. The costs 
of doing this will depend on what type of 
measurement is employed and whether 
interventions such as compression 
garments are required.
TR:   The economic benefits include 
income generation and participation. 
The people who benefit most are those 
who can make the lifestyle adjustments 
to their condition that are necessary 
to keep a job, or be as active in the 
community as they were before the 
onset of disability.  
SH:   We do know that lymphoedema 
is a chronic, disabling condition that 
potentially impacts all aspects of daily 
life. Based on available evidence to 
date, approximately 20% of survivors 
of breast, gynaecological and prostate 
cancers and melanoma will experience 
secondary lymphoedema (Hayes, 
2008). Therefore, prevention and early 
detection of lymphoedema (assuming 
early detection leads to more effective 
treatment and prevention of disease 
progression) would clearly lead to 
significant physical, social, emotional, 
financial, psychological and functional 
benefits for the individual which, in 
turn, would lead to benefits for the 
family as well as the community. The 
exact cost:benefit ratio has yet to be 
calculated and will depend on a number 
of assumptions for which good data are 
not yet available.
SR:   We know from a recently 
published study (Shih et al, 2009) that in a 
American cohort of breast cancer patients, 
whose insurance claims were examined 
for two years after cancer treatment, 
patients with lymphoedema were more 
costly to the insurance system than 
were those without. The excess medical 
costs were from $14,887 to $23,167, 
and those with lymphoedema were also 
twice as likely to have lymphangitis or 
cellulitis than those without lymphoedema. 
We also know that in this same study, 
patients with lymphoedema lost more 
productive days to healthcare office visits 
than those without lymphoedema (73.1 
vs 56.1). So we know, during the first 
two years after breast cancer treatment, 
lymphoedema is costly to both healthcare 
insurance companies that cover some 
of the expenses and to individuals with 
the condition. These data suggest that 
lymphoedema prevention not only 
would be a substantial cost saving to any 
healthcare delivery system, but also to 
those individuals who miss work seeking 
treatment for the condition. What we 
do not know, because data is currently 
unavailable, is if early detection (implying 
some sort of diagnostic procedure), 
coupled with early treatment, is less 
expensive in the long run, than delayed 
diagnosis and delayed treatment. 
Logically, it would seem patients 
may benefit from early detection. If 
they respond to treatment, infections 
are reduced, and disease progression is 
slowed. They also should benefit if early 
detection helps reduce their symptom 
burden and improves quality of life. 
The pre-operative measure-
ment of patients is often 
at a time of turmoil for the 
patient — is it worth putting 
the patient under the further 
pressure of another test?
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VK:   While it is recognised that 
undergoing treatment for cancer 
is an extremely stressful time for 
patients, tests such as limb volume 
measurements and bioimpedance are 
relatively quick and non-invasive and 
should not cause too much of a burden 
for the patient. The evidence described 
above is beginning to suggest that these 
assessments are likely to be helpful in 
preventing morbidity and, therefore, it 
would seem reasonable to offer them 
to patients.
TR:   I see full assessment as a benefit 
much desired by the patients, who 
appreciate the time spent and a detailed 
examination of their problem. 
SH:   Dealt with properly, there is no 
reason why including a lymphoedema 
measure into the mix of other pre-
operative measures should create more 
pressure for the patient. In fact, patients 
may feel a sense of reassurance that 
potential treatment sequelae are being 
anticipated and monitored in a manner 
that enables early identification and, 
therefore, management. 
SR:   A research participant with 
lymphoedema once discussed with 
me her anger that lymphoedema was 
not discussed with her before her 
treatment and her absolute inability 
to understand why her arms were not 
measured at that time (she had a full 
cardiac work-up pre-treatment) and 
on every follow-up visit. She reported 
that she had asked her surgeon about 
this and was told, ‘I don’t like to upset 
patients before surgery about this 
(lymphoedema), I don’t want you to 
decide not to have surgery because of 
this (lymphoedema).’ The woman then 
said, ‘They told me, before I ever had 
any treatment, the chemotherapy could 
permanently damage my heart and that 
a risk of anaesthesia was death. Why on 
earth would anyone think being told 
about lymphoedema or having my arms 
measured would be more traumatic 
than those two things? Or, that I would 
not have cancer treatment because of 
it? For goodness sake, I am not an idiot.’
If you use the multitude of available 
non-invasive measurement methods, 
the actual time involved in this is 
minimal. If you properly educate the 
patient about the risk and need for 
early identification of lymphoedema, 
this should not be traumatic and, yes, it 
is worth it.
Most of the parameters we 
measure (whether physical 
[limb size] or subjective [pain, 
tension, etc]) are signs of 
a failing lymphatic system. 
The only way to measure the 
functional status is by looking 
at lymphatic transport using 
lymphoscintigram. This process 
has both risks and benefits. Is 
a pre/or post-operative/post-
radiotherapy lymphoscintigram 
likely to be of benefit in high 
risk patients?
VK:   While some centres advocate 
the use of lymphoscintigraphy 
pre-operatively, e.g. to determine 
appropriate management such as 
microsurgery (Campisi, 2004) this 
is not routine practice in most. In 
the UK, lymphoscintigraphy, when 
available, is mainly used as a diagnostic 
tool and as a qualitative investigation 
(Keeley, 2006). Sometimes qualitative 
lymphoscintigraphy is reported as 
‘normal’ even in the presence of 
mild lymphoedema. Quantitative 
lymphoscintigraphy may, however, be 
more helpful. Pecking et al (1996) 
developed a ‘functional index’ which 
was abnormal in the arms in 7.5% 
of 428 women studied before 
breast cancer surgery. In those 
who had an abnormal functional 
index, 84.4% went on to develop 
clinical lymphoedema within 34 
months of surgery and radiotherapy. 
Quantitative lymphoscintigraphy 
requires standardised techniques and 
is not widely available in the UK. In the 
above study, only 7.5% of patients had 
abnormal findings pre-operatively and, 
at present, it is not known whether 
these could have been detected by 
other methods such as bioimpedance. 
Currently, there does not seem to 
be sufficient evidence to warrant the 
routine use of lymphoscintigraphy pre-
operatively.
TR:   This tool, as Pecking et al (2004) 
stated, ‘is the most advanced method 
for assessment of the lymphatic system’. 
It provides important information, so 
where it can be accessed it should be 
encouraged. However, most of the 
world’s needy cannot access it.
SH:   Sufficient evidence exists to 
demonstrate that less invasive measures, 
such as bioimpedance spectroscopy, 
provide accurate, sensitive and specific 
measures of lymphoedema status, 
particularly when pre-operative 
measures are available (Clark et al, 
2005; Rockson, 1998; Ward et al, 2001). 
Furthermore, unlike lymphoscintigraphy, 
the time and cost of assessing 
lymphoedema by bioimpedance 
spectroscopy makes it feasible for 
integration within clinical practice. In 
the future, there may be benefit for 
conducting lymphoscintigraphy for a 
small subset of women, but currently 
we do not know how to identify the 
group of women for whom this might 
be worthwhile. 
SR:   It seems ironic that we are 
concerned about ‘putting the patient 
under the  pressure of another test’ 
as we discuss the pros and cons of 
measurement, that the only functional 
test available is also the one most likely 
to cause the patient the largest amount 
of stress and highest possibility of risk of 
adverse side-effects. To determine the 
value of this test, it seems we should 
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VK: ... these assessments are likely to be helpful in preventing morbidity and, therefore, it would seem reasonable to offer them to patients.  
TR: I see full assessment as a benefit much desired by the patients.
SH: ... patients may feel a sense of reassurance that potential treatment sequelae are being anticipated and monitored...
SR: ‘They told me... the chemotherapy could permanently damage my heart and that a risk of anaesthesia was death. Why on earth would anyone think being told  
 about lymphoedema or having my arms measured would be more traumatic than those two things?’ 
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first ask, ‘What would a pre-treatment 
lymphoscintigram tell us about our 
patient that we don’t already know?’ 
In most cases, it will tell us that their 
lymphatic system is functioning well 
enough to ensure that they do not 
have lymphoedema. I would argue that 
is something we should already know 
if we are conducting adequate pre-
treatment medical histories and physical 
examinations on our patients. A medical 
history that reveals no pre-existing 
lymphoedema, an absence of patient 
reported symptoms of lymphatic failure 
(swelling, tightness, etc), and no signs of 
lymphatic malfunction during the physical 
exam tells us virtually the same thing as 
the lymphoscintigram.
A lymphoscintigram may give us an 
idea of baseline functioning, but right 
now there is no way to know for which 
patients a baseline may be helpful. Even 
under the best of circumstances, a pre-
treatment lymphoscintigram is only 
helpful if we later compare baseline 
to subsequent tests. Additionally, 
you do not have to have a baseline 
for comparison to determine, via 
lymphoscintigraphy, if there are 
abnormal findings. The risk/benefit 
ratio currently leans more toward 
risk than benefit to the patient. Less 
stressful and less risky methods such as 
infrared scanning, circumferential, and 
bioelectrical impedance methods, when 
taken at baseline and repeated on 
follow-up visits should be considered as 
more reasonable and potentially helpful 
alternatives at this time.
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VK: There is evidence that lymphoedema causes a significant impact on patients’ quality of life with a vulnerability to recurrent cellulitis, work implications, and   
 psychological morbidity (Moffatt et al, 2003).
TR: This tool, as Pecking et al (2004) stated, ‘is the most advanced method for assessment of the lymphatic system’.
SH: Sufficient evidence exists to demonstrate that less invasive measures provide accurate, sensitive and specific measures of lymphoedema status.
SR: ‘What would a pre-treatment lymphoscintigram tell us about our patient that we don’t already know?’ 
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